1. A method of treating a patient suffering from Dego disease, comprising administering to a patient suffering from Dego disease, a complement inhibitor in an amount sufficient to treat the disease or reduce the severity of one or more symptoms of the disease. The method of claim 1, wherein the complement inhibitor is administered to the patient for a long time. The method according to claim 1, further comprising identifying a patient suffering from Dego disease or with suspected Dego disease. The method of claim 1, wherein Dego disease is associated with a B19 parvovirus infection or a human immunodeficiency virus infection. The method of claim 1, wherein Dego disease is idiopathic. The method according to claim 1, wherein Dego's disease pathologically affects the gastrointestinal tract, central nervous system or cardiovascular system. The method according to claim 1, wherein Degos disease is a multi-organ systemic Degos disease. The method of claim 1, wherein Dego disease is resistant to at least one therapy selected from the group consisting of an anti-inflammatory agent, an anticoagulant, an antithrombotic agent, and an intravenously administered immunoglobulin. The method of claim 1, wherein the complement inhibitor is selected from the group consisting of soluble CR1, LEX-CR1, MCP, DAF, CD59, factor H, cobra venom factor, FUT-175, complementatin and K76 COOH. The method of claim 1, wherein the complement inhibitor is an antibody or antigen binding fragment thereof that binds to a protein of a human complement component. The method of claim 10, wherein the antibody or antigen binding fragment thereof binds to a human complement component C5 protein. The method of claim 11, wherein the complement inhibitor inhibits the degradation of the complement component C5 to fr1. Способ лечения пациента, страдающего болезнью Дего, включающий введение пациенту, страдающему болезнью Дего, ингибитора комплемента в количестве, достаточном для лечения заболевания или уменьшения
